Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3317-3327

  Syed, Nelofer ^a   Coley, Helen M ^e   Sehouli, Jalid ^g   Koensgen, Dominique ^g   Mustea, Alexander ^g   Szlosarek, Peter ^b   McNeish, Iain ^b   Blagden, Sarah P ^c   Schmid, Peter ^f   Lovell, David P ^d   Hatzimichael, Eleftheria ^h   Crook, Tim ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; POLO LIKE KINASE 2; RNA;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; DRUG CYTOTOXICITY; EPIGENETICS; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOSIS; OVARY CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RECURRENCE RISK; SERUM;

CARBOPLATIN; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; G2 PHASE; GENE SILENCING; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 79955509238     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2048     Document Type: Article

References (36)

1. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-72. (Pubitemid 26414889)
2. Simmons DL, Neel BG, Stevens R, Evett G, Erikson RL. Identification of an early growth-response gene encoding a novel putative protein kinase. Mol Cell Biol 1992;12:4164-9.
3. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3 and 4 gene expression in mammalian cells and tissues. Oncogene 2005;24:260-6.
4. Donaldson MM, Tavares AA, Hagan IM, Nigg EA, Glover DM. The mitotic role of Polo-like kinase. J Cell Sci 2001;114:2357-8.
5. Bettencourt-Dias M, Rodrigues-Martins A, Carpenter L, Riparbelli M, Lehmann L, Gatt MK, et al. SAK/PLK4 is required for centriole duplication and flagella development. Curr Biol 2005;15:2199-207. (Pubitemid 41790613)
6. Habedanck R, Stierhof YD, Wilkinson CJ, Nigg EA. The Polo kinase Plk4 functions in centriole duplication. Nat Cell Biol 2005;7:1140-6.
7. Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof YD, Nigg EA. Plk4-induced centriole biogenesis in human cells. Dev Cell 2007;13:190-202. (Pubitemid 47163610)
8. Rodrigues-Martins A, Riparbelli M, Callaini G, Glover DM, Bettencourt- Dias M. Revisiting the role of the mother centriole in centriole biogenesis. Science 2007;316:1046-50. (Pubitemid 46799494)
9. Sillibourne JE, Tack F, Vloemans N. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication. Mol Biol Cell 2010;21:547-61.
10. Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 2007;67:11106-10. (Pubitemid 350248532)
11. Pellegrino R, Calvisi DF, Ladu S, Ehemann V, Staniscia T, Evert M, et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010;51:857-68.
12. Ma S, Charron J, Erikson R. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 2003;23:6936-43. (Pubitemid 37214661)
13. Warnke S, Kemmler S, Hames RS, Tsai HL, Hoffmann-Rohrer U, Fry AM, et al. Polo-like kinase-2 is required for centriole duplication in mammalian cells. Current Biol 2004;14:1200-7. (Pubitemid 38893984)
14. Zimmerman WC, Erikson RL. Polo-like kinase 3 is required for entry into S phase. Proc Natl Acad Sci U S A 2007;104:1847-52. (Pubitemid 46239867)
15. Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, et al. Transcriptional silencing of polo-like kinase-2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006;107:250-6. (Pubitemid 43053549)
16. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry W. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells. Mol Cell Biol 2003;23:5556-71. (Pubitemid 36951322)
17. Yogasawa S, Hatakeyama S, Nakayama KI, Miyoshi H, Kohsaka S, Akazawa C. Ubiquitylation and degradation of serum-inducible kinase by hVPS18, a RING-H2 type ubiquitin-ligase. J Biol Chem 2005; 280:41619-27. (Pubitemid 41832224)
18. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129-39.
19. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004:1552-72. (Pubitemid 39491180)
20. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005;65:8961-7. (Pubitemid 41377387)
21. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009;2:34.
22. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63:132-6. (Pubitemid 20234682)
23. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004;64:2502-8. (Pubitemid 38523906)
24. Fu Y, Ye D, Chen H, Lu W, Ye F, Xie X. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol 2007;105:66-73. (Pubitemid 46441441)
25. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11:498-512. (Pubitemid 46856907)
26. Gy€orffy B, Surowiak P, Kiesslich O, Denkert C, Sch€afer R, Dietel M, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006;118:1699-712. (Pubitemid 43376433)
27. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94: 1087-92.
28. de Viron E, Knoops L, Connerotte T, Smal C, Michaux L, Saussoy P, et al. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2- chlorodeoxyadenosine: a potential marker of defective damage response. Br J Haematol 2009;147:641-52.
29. Bredberg A, Bodmer W. Cytostatic drug treatment causes seeding of gene promoter methylation. Eur J Cancer 2007;43:947-54. (Pubitemid 46366686)
30. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10:4420-6. (Pubitemid 38878884)
31. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multi-drug resistant MCF-7 breast adenocarcinomas cells reveals novel hyper-and hypomethylated targets. Mol Cancer Ther 2007;6:1089-98. (Pubitemid 46554580)
32. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Rep 2009; 18:47-56.
33. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997;57: 850-6. (Pubitemid 27098008)
34. Gore ME, Preston N, A'Hern RP, Hill C, Mitchell P, Chang J, et al. Platinum-Taxol non-cross-resistance in epithelial ovarian cancer. Br J Cancer 1995;71:1308-10.
35. Hummel M, Bentick S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biological definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Medicine 2006;354: 2419-30. (Pubitemid 43855045)
36. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 2009;45: 1129-36.